These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21510895)

  • 41. Open-label use of placebos in the treatment of ADHD: a pilot study.
    Sandler AD; Bodfish JW
    Child Care Health Dev; 2008 Jan; 34(1):104-10. PubMed ID: 18171451
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
    Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic response in children with ADHD: role of observers and settings.
    Bhat V; Sengupta SM; Grizenko N; Joober R
    World J Pediatr; 2020 Jun; 16(3):314-321. PubMed ID: 31965445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short-term efficacy and tolerability of methylphenidate in children with traumatic brain injury and attention problems.
    Ekinci O; Direk MÇ; Gunes S; Teke H; Ekinci N; Yıldırım F; Okuyaz Ç
    Brain Dev; 2017 Apr; 39(4):327-336. PubMed ID: 27903419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study.
    Gothelf D; Gruber R; Presburger G; Dotan I; Brand-Gothelf A; Burg M; Inbar D; Steinberg T; Frisch A; Apter A; Weizman A
    J Clin Psychiatry; 2003 Oct; 64(10):1163-9. PubMed ID: 14658963
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
    Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts.
    Stein MA; Waldman ID; Charney E; Aryal S; Sable C; Gruber R; Newcorn JH
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):581-8. PubMed ID: 22136094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
    Buitelaar JK; Sobanski E; Stieglitz RD; Dejonckheere J; Waechter S; Schäuble B
    J Clin Psychiatry; 2012 Aug; 73(8):1097-102. PubMed ID: 22780962
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of vitamin D supplementation as adjunctive therapy to methylphenidate on ADHD symptoms: A randomized, double blind, placebo-controlled trial.
    Mohammadpour N; Jazayeri S; Tehrani-Doost M; Djalali M; Hosseini M; Effatpanah M; Davari-Ashtiani R; Karami E
    Nutr Neurosci; 2018 Apr; 21(3):202-209. PubMed ID: 27924679
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder.
    Reimherr FW; Williams ED; Strong RE; Mestas R; Soni P; Marchant BK
    J Clin Psychiatry; 2007 Jan; 68(1):93-101. PubMed ID: 17284136
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study.
    Matthijssen AM; Dietrich A; Bierens M; Kleine Deters R; van de Loo-Neus GHH; van den Hoofdakker BJ; Buitelaar JK; Hoekstra PJ
    Am J Psychiatry; 2019 Sep; 176(9):754-762. PubMed ID: 31109200
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anxiety and depression symptoms and response to methylphenidate in children with attention-deficit hyperactivity disorder and tic disorder.
    Gadow KD; Nolan EE; Sverd J; Sprafkin J; Schwartz J
    J Clin Psychopharmacol; 2002 Jun; 22(3):267-74. PubMed ID: 12006897
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug and placebo side effects in methylphenidate-placebo trial for attention deficit hyperactivity disorder.
    Fine S; Johnston C
    Child Psychiatry Hum Dev; 1993; 24(1):25-30. PubMed ID: 8404241
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.
    Retz W; Rösler M; Ose C; Scherag A; Alm B; Philipsen A; Fischer R; Ammer R;
    World J Biol Psychiatry; 2012 Jan; 13(1):48-59. PubMed ID: 21155632
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Spencer TJ; Greenbaum M; Ginsberg LD; Murphy WR
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):501-10. PubMed ID: 19877974
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.